POLYEPEPTIDES CONTAINING An Fc SITE WHICH DEMONSTRATE AN INCREASED EFFECTIVE FUNCTION THANKS TO CHANGES TO THE FOCOSILATION DEGREE, AND THE METHODS FOR THEIR APPLICATION

摘要

1. A method of attenuating post-translational fucosylation of a human IgG Fc region, which comprises modifying said Fc region to include amino acid substitution at position: L234, L235, F243, R292, Y300, V305 or P396, and expressing said Fc region in the host cell capable of mediating normal glycosylation. 2. The method of claim 1, wherein said Fc region comprises an amino acid substitution at position F243, R292, Y300, or P396.3. The method of claim 2, wherein: (a) said substitution at position F243 is F243C, F243L or F243R; (b) said substitution at position R292 is R292G, R292L, R292M, R292P, R292S or R292Y; (c) said substitution at position Y300 is Y300L; (d) said substitution at position P396 is P396L. 4. The method of claim 1, wherein said Fc region exhibits altered affinity for a CD16A receptor, a CD16B receptor, or a CD32A receptor. The method of claim 4, wherein said Fc region exhibits reduced affinity for the CD32B.6 receptor. The method of claim 4, wherein said Fc region exhibits increased affinity for the CD16A receptor. The method of claim 1, wherein said Fc region is an Fc region of a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, or a single chain antibody that contains said heavy and light chains. The method of claim 7, wherein said antibody specifically binds CD16A, CD32B, HER2 / neu, A33, CD5, CD11c, CD19, CD20, CD22, CD23, CD27, CD40, CD45, CD79a, CD79b, CD103, CTLA4, ErbB1, ErbB3 ErbB4, VEGF receptor, TNF-α receptor, TNF-ß receptor, or TNF-γ receptor CD16A. 9. The method of claim 7, wherein said antibody specifically binds a cancer antigen. The method according to claim 9, where the specified malignant tumor is a malignant tumor of the breast,